Possible Risk of Thrombotic Events following Oxford-AstraZeneca COVID-19 Vaccination in Women Receiving Estrogen.
Biomed Res Int
; 2021: 7702863, 2021.
Article
in English
| MEDLINE | ID: covidwho-1484107
ABSTRACT
People who receive the ChAdOx1 nCoV-19 vaccine, particularly perimenopausal women who are on birth control or postmenopausal women who take estrogen supplements, may experience thrombosis and thrombocytopenia. Estrogen and the ChAdOx1 nCoV-19 vaccine both have the potential to cause thrombus in different ways. Some postmenopausal women who are also taking estrogens may develop thrombosis and thrombocytopenia after receiving the ChAdOx1 nCoV-19 vaccine. Therefore, women are encouraged to stop taking drugs containing estrogen before receiving this vaccine. Furthermore, consuming fish oil can help reduce the risk of developing blood clots among women who are in the luteal phase and, thus, have high estrogen levels. In addition, ChAdOx1 nCoV-19's side effects in young women could be mitigated by administering it during the follicular phase.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Thrombosis
/
Vaccination
/
Estrogens
/
COVID-19 Vaccines
/
COVID-19
Type of study:
Prognostic study
Topics:
Vaccines
Limits:
Female
/
Humans
Language:
English
Journal:
Biomed Res Int
Year:
2021
Document Type:
Article
Affiliation country:
2021
Similar
MEDLINE
...
LILACS
LIS